SeeGen, Microsoft, and Springer Nature leadership's first round table"Technology sharing business in earnest"
Oct 24, 2024
|
Seegene said on the 23rd (local time) that the management representing each company attended the first Technology-Sharing Initiative Partner Round Table held in London, England, to share their progress and express sympathy on various cooperation measures. The meeting was attended by Seegene CEO Chun Jong-yoon, Springer Nature Chief Operating Officer Marc Spenole, Springer Nature Research Division President Steven Inchcombe, and Microsoft Global Health and Life Sciences Division Director Elena Bonfiglioli.
Chun Jong-yoon, CEO of Seegene, said "We will devise and implement a plan to join forces with experts such as all companies and scientists participating in the technology sharing business through synergy that will be generated by Seegene's unique technologies such as syndromic quantitative PCR technology, Microsoft's world-leading AI and cloud services, and Springer Nature's world-leading scientific community."
The ultimate goal of the technology sharing project is to create a disease-free world not only for humans but also for all animal and plant communities by sharing Cizen's technology and know-how, which is represented by the Syndromic Quantitative PCR Technology and the Reagent Development Automation System (SGDDS), with scientists and other experts from around the world participating in developing local customized diagnostic products in various fields related to human and animal diseases. Companies around the world that will participate in the technology sharing business will have the infrastructure to develop and produce locally optimized syndrome quantitative PCR products based on the world's best PCR technology and know-how provided by Seegene.
Based on the achievements derived from this roundtable, a declaration ceremony will be held in the second half of next year to declare the `realization of a world free from disease.' At next year's declaration ceremony, a plan to maximize synergy will be derived based on the consensus formed at this roundtable.
During the reagent development process, Seegene shared initial results related to automation in the research and planning stage using Microsoft's Azure OpenAI Service. In addition, Microsoft Fabric, Microsoft's AI-based data integration platform, was used to demonstrate the initial performance of a syndrome-based statistical analysis system that helps accurate diagnosis by finding correlations between various pathogens causing similar symptoms.
CEO Chun Jong-yoon expressed expectations, saying, `If scientists and other experts use their limited disease-related data and use diagnostic information from around the world and Microsoft's AI services, they will be able to immediately cope with any disease in the future.'
Elena Bonfigioli, Director of Microsoft's Global Health and Life Sciences Division, commented "Seegene and Microsoft shared their vision for a new generation of diagnostic solutions that are easily accessible to all to help people stay healthy for longer"Cloud and AI technologies secure vast amounts of data needed to track disease diagnosis trends around the world in real time, and are used to logically process and analyze them." "Microsoft is the most reliable partner to realize Seegene's vision of creating a 'disease-free world implementation'," he added.
Seegene and Microsoft signed an agreement on strategic cooperation in January this year and are incorporating various services, including Microsoft's Azure Open AI service, into Seegene's Development Automation System (SGDDS).
Meanwhile, Seegene and Springer Nature have been conducting the Open Innovation Program Powered by Seegene (OIP), a global diagnostic reagent development contest project, since last year. Beginning this year, the second year, it will be a new public offering project to develop diagnostic reagents for Springer Nature's global award program, 'Nature Awards MDx Impact Grants'. It will be held in the form of an open task in which product development ideas are directly proposed from applicants around the world, and it is expected that Springer Nature will lead most of the processes, including task competition and screening, to attract a lot of participation from the scientific community.
Seegene and Springer Nature signed a strategic alliance agreement in May this year that included OIP advancement. First of all, it plans to actively induce the global scientific community secured by Springer Nature to participate in the development of new reagents.
Mark Spagnol Springer, COO of Nature, who attended the roundtable of technology sharing business, said "MDx Impact Grant has high expectations for synergy in conjunction with technology sharing businesses."We will work together to create an ecosystem where marginalized patients around the world can receive accurate and rapid diagnosis more easily."
Following the roundtable of partners in the technology sharing business, the European OIP Awards were held to award and encourage last year's Open Innovation Program (OIP) winners.
The European OIP Awards announced the winners of eight scientists working in Europe out of 17 winners from around the world. The list of winners is △Ulrich Eigner (Germany) △Gian Maria Rosolini (Italy) △Bismara Ciara Sylvia (Italy) △Davey Van den Wurek (Belgium) △Nicholasin (Belgium) △Piet Kouls (Belgium) △Coa Thailand (Netherlands) △Petro Vieira-Baptista (Portugal).
compact@sportschosun.com
